![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biodynamics Plc | LSE:OBD | London | Ordinary Share | GB00BD5H8572 | ORD GBP0.01 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.14% | 7.38 | 7.02 | 7.74 | 7.80 | 7.80 | 7.80 | 95,652 | 16:35:06 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 1.34M | -10.83M | -0.0535 | -1.46 | 15.78M |
TIDMOBD
RNS Number : 0421P
Oxford BioDynamics PLC
06 October 2023
Oxford BioDynamics Plc
( "OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
6 October 2023 - Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that Vulpes Life Sciences Fund, which is controlled by Non-Executive Director, Stephen Diggle, has sold 115,000 Ordinary Shares of 1 pence each ("shares") at an average price of 45.2p.
Following this transaction, through the holdings of Vulpes Life Sciences Fund and Vulpes Testudo Fund, Stephen Diggle is interested in a total of 28,333,756 shares, representing approximately 14.01% of the Company's current issued share capital.
The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further details:
Details of the person discharging managerial responsibilities/person 1 closely associated a) Name Stephen Diggle ------------------------------- -------------------------------------- Reason for the notification 2 ----------------------------------------------------------------------- a) Position/status Director/ PDMR ------------------------------- -------------------------------------- b) Initial notification/ Initial notification Amendment ------------------------------- -------------------------------------- Details of the issuer, emission allowance market participant, 3 auction platform, auctioneer or auction monitor ----------------------------------------------------------------------- a) Name Oxford BioDynamics Plc ------------------------------- -------------------------------------- b) LEI 2138005Y1TK258O5U928 ------------------------------- -------------------------------------- Details of the transaction(s): section to be repeated for 4 (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----------------------------------------------------------------------- a) Description of the Ordinary Shares of 1 pence each financial instrument, type of instrument ISIN: GB00BD5H8572 Identification code ------------------------------- -------------------------------------- b) Nature of the transaction Sale of ordinary shares ------------------------------- -------------------------------------- c) Price(s) and volume(s) Price(s) Volume(s) GBP0.452 115,000 ---------- ------------------------------- -------------------------------------- d) Aggregated information Price Volume - Aggregated volume GBP0.452 115,000 - Price -------- ------------------------------- -------------------------------------- e) Dates of the transactions 4 October 2023 ------------------------------- -------------------------------------- f) Place of the transaction London Stock Exchange (XLON) ------------------------------- --------------------------------------
-Ends-
For further details please contact:
Oxford BioDynamics Plc Tel: +44 (0)1865 Jon Burrows, CEO 518910 Paul Stockdale, CFO Shore Capital - Nominated Adviser and Tel: +44 (0)20 Broker 7408 4090 Stephane Auton / Iain Sexton Instinctif Partners Tel: +44 (0)20 Melanie Toyne-Sewell / Rozi Morris 7457 2020 Adam Loudon / Jack Kincade OxfordBioDynamics@instinctif.com
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship products are the EpiSwitch(R) CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch(R) PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, which has been launched in the US and UK in September 2023.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch(R) CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch(R) Explorer Array Kit , which is available for purchase by the life science research community.
The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch(R), which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website, www.oxfordbiodynamics.com , or follow OBD on Twitter (@OxBioDynamics) and LinkedIn .
About EpiSwitch(R)
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch(R) can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch(R) is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch(R) data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHFLFSRILLRIIV
(END) Dow Jones Newswires
October 06, 2023 12:44 ET (16:44 GMT)
1 Year Oxford Biodynamics Chart |
1 Month Oxford Biodynamics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions